A Mindset for Hyper Growth

In a deal-starved private equity landscape, Patrick Pulvermueller, Chair of WebPros, demonstrates a unique ability to unlock value and scale businesses through targeted acquisitions. In an interview with Criticaleye’s Emily Jones, Patrick reveals key insights on driving innovation and expanding Board capabilities in challenging conditions.

Criticaleye provides Chairs, NEDs and SIDs with bespoke support designed to nurture high performance at Board level. With 56 percent of respondents in our Chair & NED Research saying they strongly believe Boards require external reference points, Criticaleye facilitates a unique environment to benchmark with Board-level peers from various organisations, sectors and regions.

 
Click here to find out more about how we support Board leaders.




Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.

Click here to download this insight
Inside the Take-private at Pr...

After a whirlwind journey from the NYSE to private ownership, PropertyGuru CFO Joe Dische reflects on making the hard calls. In this interview with Criticaleye Senior Editor Bridgette Hall, he discusses public vs privat...

Inspiring Leaders Podcast: Le...

Rob Hornby, Co-CEO of AlixPartners and Rita Clifton CBE, Portfolio Chair and Non-Executive Director (including Deputy Chair of the John Lewis Partnership, Chair of Simplyhealth, Chair of the international sustainability...

Inspiring Leaders Podcast: De...

Lucinda Charles-Jones, Non-executive Director & Chair or RemCo for Virgin Money and Rank Group (plus a Criticaleye Board Mentor) and Jim Devine, Group HRD, Spirax Group speak to us about some of the findings of our ...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 297




NatWest Group Legal & General Worldpay IBM Consulting London Stock Exchange Group Rolls-Royce Hitachi Solutions NATS Workday Concentrix Salesforce Google British Land FTSE Women Leaders Review Palo Alto Networks Accenture Lightsource bp E.ON UK AlixPartners Drax Group plc Eightfold AI Aldermore Group GlaxoSmithKline plc